Therapie mit Immunglobulinen

  • C. Mueller-Eckhardt
Chapter

Zusammenfassung

Die Therapie mit Immunglobulinen ist etwa 100 Jahre alt. Sie begann mit der Entdeckung E. von ßehring’s und O. Kitasako’s (1890), daß sich mit dem Serum eines immunisierten Schafes eine Schutzwirkung gegen Diphthe-rietoxine erzielen läßt [9]. Diese Therapieform wurde als passive Immunisierung bezeichnet. Die in der Folgezeit entwickelten, xenogenen Antiseren gegen zahlreiche Infektionserreger hatten den Nachteil, daß sie rasch zur Immunisierung der Patienten gegen das Fremdeiweiß führten und eine „Serumkrankheit“ auslösten. Neue Wege der Immunglo-bulintherapie eröffneten sich erst, als es Cohn und Mitarbeitern in den vierziger Jahren gelang, im großtechnischen Maßstab menschliche Proteine aus Humanplasma (siehe Kapitel V.) zu gewinnen.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ, Nelson J, Ochs H, Stiehm ER, Tiller T, Wara DW, Wedgwood R (1982) Use of intravenous y-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 22:60–67.PubMedCrossRefGoogle Scholar
  2. 2.
    Arsura EL, Blick A, Brunner NG, Namba T, Grob D (1986) High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 146:1365–1368.PubMedCrossRefGoogle Scholar
  3. 3.
    Atrah HI, Sheehan T, Gribben J, Crawford RJ, O’Donnel JR, Sandilands DP (1986) Improvement of post platelet transfusion increments following intravenous immunoglobulin therapy för leukaemic HLA-immunized patients. Scand J Haematol 36:160–164.PubMedCrossRefGoogle Scholar
  4. 4.
    Balzereit F, Fateh-Moghadam A, Besinger KA, Geursen RG (1986) Myasthenia gravis. MMW 128:654–657.Google Scholar
  5. 5.
    Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous administration of human gamma globulin. Vox Sang 7:157.PubMedCrossRefGoogle Scholar
  6. 6.
    Barandun S, Skvaril F, Morell A (1976) Prophylaxe und Therapie mit γ-Globulin. Allgemeine Charakterisierung und klinische Anwendung von γ-Globulin-Präparaten. Schweiz Med Wo-chenschr 106:533–542, 580–586.Google Scholar
  7. 7.
    Becker T, Panzer S, Maas D, Kiefel V, Sprenger R, Kirschbaum M, Mueller-Eckhardt C (1985) High-dose intravenous immunoglobulin för posttransfusion purpura. Br J Haematol 61:149–155.PubMedCrossRefGoogle Scholar
  8. 8.
    Becton DL, Kinney TR, Chaffee S, Kurtzberg J, Friedman HS, Falleta JM (1984) High-dose intravenous immunoglobulin för severe platelet alloimmunization. Pediatrics 74:1120–1123.PubMedGoogle Scholar
  9. 9.
    Behring E von, Kitasato O (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113–1114.CrossRefGoogle Scholar
  10. 10.
    Berlin G, Selbing A, Ryden G (1985) Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1:1153.PubMedCrossRefGoogle Scholar
  11. 11.
    Bierling P, Cordonnier C, Rodet M, Vernant JP, Pesce A, Rochant H, Duedari N (1984) High dose intravenous gammaglobulin and platelet transfusions in leukaemic HLA-immunized patients. Scand J Haematol 33:215:220.Google Scholar
  12. 12.
    Bing DH (1984) Complement interaction with immune serum globulin and immune globulin intravenous. Am J Med 76(3A):19–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Burks AW, Sampson HA, Buckley RB (1986) Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314:560–564.PubMedCrossRefGoogle Scholar
  14. 14.
    Bussel A, Jaisson F, Janvier M, Traulle C (1983) Utilisation des gammaglobulines intraveineuses à fortes doses dans le traitement des anémies hémolytiques auto-immunes. Presse Med 41:2628.Google Scholar
  15. 15.
    Béris P, Audétat F, Beyner F, Pittet D, Jeanett M, Miescher PA (1985) Hautes doses d’immu-noglobulines par voie intraveineuse pour le traitement des neutropénics „auto-immunes“. Schweiz Med Wochenschr 115:1512–1514.PubMedGoogle Scholar
  16. 16.
    Clarke C (1983) Prevention of Rh hemolytic disease by immunoglobulin anti-D. Vox Sang 44:396–399.PubMedCrossRefGoogle Scholar
  17. 17.
    Collins MS, Roby RE (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against polysaccharide antigens för Pseudomonas aeruginosa. Am J Med 76(3A):168–174.PubMedCrossRefGoogle Scholar
  18. 18.
    Condie RM, O’Reilly RJ (1984) Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am J Med 76(3 A): 134–141.PubMedCrossRefGoogle Scholar
  19. 19.
    Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections (1983) Multicenter randomized controlled trial on the efficacy of additional immunglobulin therapy in cases of diffuse fibrino-purulent peritonitis. Klin Wochenschr 61:445.CrossRefGoogle Scholar
  20. 20.
    Cunningham-Rundles C (1985) Intravenous immune serum globulin in immunodeficiency. Vox Sang 49 (Suppl. 1):8–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Day NK, Good RA, Wahn V (1984) Adverse reactions in selected patients following intravenous infusions of gamma globulin. Am J Med 76(3A):8–14.CrossRefGoogle Scholar
  22. 22.
    Derycke M, Dreyfus M, Ropert JC, Tchernia G (1985) Intravenous immunoglobulin för neonatal isoimmune thrombocytopenia. Arch Dis Child 60:667–679.PubMedCrossRefGoogle Scholar
  23. 23.
    Editorial (1983) Antiserum för gram-negative bacteraemia. Lancet 1:967–968.Google Scholar
  24. 24.
    Fateh-Moghadam A, Wick M, Besinger U, Geursen RG (1984) High-dose intravenous gammaglobulin för myasthenia gravis. Lancet 1:848–849.PubMedCrossRefGoogle Scholar
  25. 25.
    Fehr J, Hofmann V, Kappeier U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254–1258.PubMedCrossRefGoogle Scholar
  26. 26.
    Flik J, Milbradt H, Wahlers T, Schäfers HJ, Ha-verich A (1987) Passagere HIV-Antikörper-Po-sivität bei Herztransplantierten nach wiederholter Applikation eines CMV-Immunoglobulin-präparates. Dtsch Med Wochenschr 112:178–181.PubMedCrossRefGoogle Scholar
  27. 27.
    Furth R van, Leijh PCL (1981) Functional interactions of various commercial gammagobulin preparations with staphlococcus aureus and granulocytes. In: Nydegger UE (ed) Immunotherapy, Academic Press, London pp. 181–190.Google Scholar
  28. 28.
    Furusho K, Nakano H, Shinomiya K, Tamura T, Manabe Y, Kawarano M, Baba K, Kamiya T, Kiyosawa N, Hayashidera T, Hirose O, Yokoy-ama T, Baba K, Mori C (1984) High-dose intravenous gammaglobulin för Kawasaki disease. Lancet 11:1055–1058.CrossRefGoogle Scholar
  29. 29.
    Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A (1985) Polyvalent immunoglobulins för prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 11:288–294.PubMedCrossRefGoogle Scholar
  30. 30.
    Gocke DJ, Raska K Jr, Pollack W, Schwartzer T (1986) HTLV-III antibody in commercial immunoglobulin. Lancet 1:37–38.PubMedCrossRefGoogle Scholar
  31. 31.
    Gronski P, Hofstaetter T, Kanzy EJ, Lüben G, Seiler FR (1983) S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application. I. Physico-chemical and binding properties of S-sulfonated and reconstituted IgG. Vox Sang 45:144–145.PubMedCrossRefGoogle Scholar
  32. 32.
    Grundmann R, Thul P, Pichlmaier H (1985) Prophylaktische Immunglobulingabe nach größeren Magenresektionen. Dtsch Med Wochenschr 110:529–533.PubMedCrossRefGoogle Scholar
  33. 33.
    Hansi W, Kratzsch G, Heimpel H (1980) Klinische Erfahrungen mit einem neuen intravenös applizierbaren Immunoglobulin-Präparat. Dtsch Med Wochenschr 105:1675–1680.PubMedCrossRefGoogle Scholar
  34. 34.
    Heiner DC (1984) Significance of immunoglobulin G subclasses. Am J Med 76:1–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Heiner DC (1986) IgG subclass composition of intravenous immunoglobulin preparations: Clinical relevance. Rev Infect Dis 8:374–381.CrossRefGoogle Scholar
  36. 36.
    Heinze E, Thon A, Vetter U, Gaedicke G, Zup-pinger K (1985) Gammaglobulin therapy in 6 newly diagnosed diabetic children. Acta Paediatr Scand 74:605–606.PubMedCrossRefGoogle Scholar
  37. 37.
    Hässig A (1986) Intravenous immunoglobulins: pharmacological aspects and therapeutic use. Vox Sang 51:10–17.PubMedCrossRefGoogle Scholar
  38. 38.
    Imaizumi A, Suzuki Y, Sato H, Sato Y (1985) Protective effects of human gamma-globulin preparations against experimental aerosol infections of mice with bordetella pertussis. Vox Sang 48:18–25.PubMedCrossRefGoogle Scholar
  39. 39.
    Imbach P, Barandun S, d’Apuzzo V, Baumgart-ner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin för idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231.PubMedCrossRefGoogle Scholar
  40. 40.
    Imbach P, Berchtold W, Hirt A, Mueller-Eck-hardt C, Rossi E, Wagner HP, Gaedicke G, Joller P, Müller B, Barandun S (1985) Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 11:463–468.Google Scholar
  41. 41.
    Iwata M, Ajiki Y (1986) Effect of human immunoglobulin preparations on experimental Bordetella pertussis infection in mice. Vox Sang 51:176–181.PubMedCrossRefGoogle Scholar
  42. 42.
    Jilg W, Deinhardt F (1985) Immunprophylaxe der Virushepatitis. Dtsch Med Wochenschr 110:728–730.PubMedCrossRefGoogle Scholar
  43. 43.
    John TJ, Ninan GT, Rajagopalan MS, John F, Flewett TH, Francis DP, Zuckerman AJ (1979) Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet 1:1074PubMedCrossRefGoogle Scholar
  44. 44.
    Jones RJ, Roe EA, Gupta JL (1980) Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet 11:1263–1265.CrossRefGoogle Scholar
  45. 45.
    Jungi TW, Santer M, Lerch PG, Barandun S (1986) Effect of various treatments of gammaglobulin (IgG) för achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang 51:18–26.PubMedCrossRefGoogle Scholar
  46. 46.
    Just HM, Metzger M, Vogel W, Pelka RB (1986) Einfluß einer adjuvanten Immunglobulinthera-pie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station. Klin Wochenschr 64:245–256.PubMedCrossRefGoogle Scholar
  47. 47.
    Kekomäki R, Elfenbein G, Gardner R, Graham-Pole J, Mehta P, Gross S (1984) Improved response of patients refractory ro random-donor platelet transfusions by intravenous gamma globulin. Am J Med 76(3A): 199–203.PubMedCrossRefGoogle Scholar
  48. 48.
    Laurian Y, Le Bras P, Ellrodt A, Alvin P (1986) Immune thrombocytopenia, gammaglobulin, and seropositivity to the human T-lymphotropic virus type III. Ann Intern Med 105:145.PubMedCrossRefGoogle Scholar
  49. 49.
    Lever AML, Brown D, Webster ADB, Thomas HC (1984) Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 11:1062–1964.CrossRefGoogle Scholar
  50. 50.
    Lindquist L, Lundbergh P, Maasing R (1981) Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia. Vox Sang 40:329–337.PubMedCrossRefGoogle Scholar
  51. 51.
    Ludwig H, Knapp W (1980) Erworbene Agammaglobulinämie. Dtsch Med Wochenschr 105:194–201.PubMedCrossRefGoogle Scholar
  52. 52.
    Lundblad JL, Mitra G, Sternberg MM, Schroe-der DD (1986) Comparative studies of impurities in intravenous immunoglobulin preparations (Gamimune, Endobulin, Gammagard, Gam-monativ, Immunoglobulin 7S, Intraglobin, San-doglobulin, Venimmun). Rev Infect Dis 8:382–390.CrossRefGoogle Scholar
  53. 53.
    Masuda K, Makula MF, Okuyama K, Ishiyama H, Yasuda J (1982) Antibody spectrum and anticomplementary activity of a plasmin-treated immunoglobulin preparation. Vox Sang 42:8–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Masuho Y, Tomibe K, Matsuzawa K, Ohtsu A (1977) Development of an intravenous γ-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human γ-globulin. Vox Sang 32:175–181.PubMedCrossRefGoogle Scholar
  55. 55.
    McClelland DB, Yap PL (1984) Clinical use of immunoglobulins. Clin Haematol 13:39–73PubMedGoogle Scholar
  56. 56.
    McVerry BA, Spearing R, Smith A (1985) SLE anticoagulant: transient inhibition by high dose immunoglobulin infusions. Br J Haematol 61:579–580.PubMedCrossRefGoogle Scholar
  57. 57.
    Mollison PL (1983) Blood transfusion in clinical medicine, 7th Edition. Blackwell Scientific Publications, Oxford pp. 187–190.Google Scholar
  58. 58.
    Morbidity and Mortality Weekly Report (1986) Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 35:231–233.Google Scholar
  59. 59.
    Morell A (1987) Störungen der humoralen Immunität. In: Wahn U, Seger R, Wahn V (ed) Pädiatrische Allergologie und Immunologie in Klinik und Praxis. G. Fischer, Stuttgart.Google Scholar
  60. 60.
    Morell A, Barandun S (1985) Use of immunoglobulins. In: Das PC (ed) Supportive therapy in haematology, Martinus Nijhoff Publishers, Bo-ston/Dordrecht/Lancester pp. 235–244.CrossRefGoogle Scholar
  61. 61.
    Morell A, Skvaril F (1980) Struktur und biologische Eigenschaften vom Immunglobulinen und γ-Globulin-Präparaten. II. Eigenschaften von γ-Globulin-Präparaten. Schweiz Med Wochenschr 110:80–85.PubMedGoogle Scholar
  62. 62.
    Morell A, Schürch B, Ryser D, Hofer F, Skvaril F, Barandun S (1980) In vivo behaviour of gamma globulin preparations. Vox Sang 38:272–283.PubMedCrossRefGoogle Scholar
  63. 63.
    Morell A, Schnoz M, Barandun S (1982) Buildup and maintenance of IgG serum concentrations with intravenous immunoglobulin in patients with primary humoral immunodeficiency. Vox Sang 43:212–219.PubMedCrossRefGoogle Scholar
  64. 64..
    Mueller-Eckhardt C, Küenzlen E (1984) Alloimmune thrombocytopenia of the newborn. In: Engelfriet CP, Loghem JJ van, Borne AEGKr von dem (ed) Immunohematology, Elsevier Science Publishers, B.V., Amsterdam pp. 166–177.Google Scholar
  65. 65.
    Mueller-Eckhardt C, Salama A, Mahn I, Kiefel V, Neuzner J, Graubner M (1985) Lack of efficacy of high-dose intravenous immunoglobulin in autoimmune haemolytic anaemia: a clue to its mechanism. Scand J Haematol 34:394–400.PubMedCrossRefGoogle Scholar
  66. 66.
    Murait Gv, Sidiropoulos D (1981) Intravenous Ig substitution therapy in the treatment of septicemia in preterm neonates. In: Nydegger UE (ed) Immunohemotherapy, Academic Press, London pp. 313–324.Google Scholar
  67. 67.
    Neu I, Pfaffenrath V, Pelka RB (1980) Klinische und statistische Untersuchungen über den therapeutischen Wert von intrathekal injizierten Immunglobulinen bei infektiös-entzündlichen Erkrankungen des zentralen Nervensystems. Therapiewoche 30:3024–3032.Google Scholar
  68. 68.
    Newburger Jane W, Takahashi M, Burns JC, Bei-ser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki Syndrome with intravenous gamma globulin. N Engl J Med 315:341–347.PubMedCrossRefGoogle Scholar
  69. 69.
    Newland AC (1984) The use of intravenous IgG in immune cytopenias — a review. Apheresis Bulletin 2:13–23.Google Scholar
  70. 70.
    Newland AC, Macey MG, Bubel M (1984) IgE in intravenous IgG. Lancet 1:1406–1407.PubMedCrossRefGoogle Scholar
  71. 71.
    Oxelius V-A (1984) Immunoglobulin G (IgG) subclasses and human disease. Am J Med 76(3A):7–18PubMedCrossRefGoogle Scholar
  72. 72.
    Panzer S, Zeitelhuber U, Hach V, Brackmann H, Niessner H, Mueller-Eckhardt C (1986) Immune thrombocytopenia in severe hemophilia A treated with high-dose intravenous immunoglobulin. Transfusion 26:69–72.PubMedCrossRefGoogle Scholar
  73. 73.
    Pineda AA, Taswell HF (1975) Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion 15:10–15.PubMedCrossRefGoogle Scholar
  74. 74.
    Pirofsky B (1984) Intravenous immune globulin therapy in hypogammaglobulinemia. Am J Med 76(3A):53–60.PubMedCrossRefGoogle Scholar
  75. 75.
    Pollack M (1979) Antibody mediated immunity on Pseudomonas disease and its clinical application. In: Alwing BM, Finlayson JS (ed) Immunoglobulins. Characteristics and uses of intravenous preparations, DHHS, p 73.Google Scholar
  76. 76.
    Pollack S, Cunningham-Rundles C, Smithwick EM, Barandun S, Good RA (1982) High-dose intravenous gamma globulin för autoimmune neutropenia. N Engl J Med 307:253.PubMedCrossRefGoogle Scholar
  77. 77.
    Riesen W (1980) Struktur und biologische Eigenschaften von Immunglobulinen und γ-Globulin-Präparaten. I. Struktur und Funktion von Immunglobulinen. Schweiz Med Wochenschr 110:74–79.PubMedGoogle Scholar
  78. 78.
    Ring J, Duswald KH (1980) Probleme der intravenösen Gammaglobulintherapie. Klin Wochenschr 58:797–809.PubMedCrossRefGoogle Scholar
  79. 79.
    Rohr G, Kusterer K, Schule M, Gladisch R, Schwedes U, Teuber J, Usadel KH (1987) Treatment of Crohn’s disease and ulcerative colitis with 7S-immunoglobulin. Lancet 1:170.PubMedCrossRefGoogle Scholar
  80. 80.
    Roifman CM, Lederman HM, Lavi S, Stein LD, Levison H, Gelfand EW (1985) Benefit of intravenous IgG replacement in hypogammaglobuli-nemic patients with chronic sinopulmonary disease. Am J Med 79:171–174.PubMedCrossRefGoogle Scholar
  81. 81.
    Rosen FS, Cooper MD, Wedgwood RJP (1984) The primary immunodeficiencies (First of two parts). N Engl J Med 311:235–242.PubMedCrossRefGoogle Scholar
  82. 82.
    Rosen FS, Cooper MD, Wedgwood RJP (1984) The primary immunodeficiencies (Second of two parts). N Engl J Med 311:300–310.PubMedCrossRefGoogle Scholar
  83. 83.
    Römer J, Morgenthaler J-J, Scherz R, Skvaril F (1982) Characterization of various immunoglobulin preparations för intravenous application. I. Protein composition and antibody content. Vox Sang 42:62–73.PubMedGoogle Scholar
  84. 84.
    Römer J, Späth PJ, Skvaril E, Nydegger UE (1982) Characterization of various immunoglobulin preparations för intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang 42:74–80.PubMedGoogle Scholar
  85. 85.
    Scheiermann N, Gesemann M, Riffelmann HD (1985) Nachweis von Anti-HTLV-III-Antikör-pern in Gammaglobulinpräparaten zur intramuskulären Injektion. Dtsch Med Wochenschr 110:1912–1913.PubMedCrossRefGoogle Scholar
  86. 86.
    Schiffer CA, Hogge DE, Aisner J, Dutcher JP, Lee EJ, Papenberg D (1984) High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 64:937–940.PubMedGoogle Scholar
  87. 87.
    Schmidt RE, Budde U, Bröschen-Zywietz C, Schäfer G, Mueller-Eckardt C (1984) High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP) — Clinical effects. Blut 48:19–25.PubMedCrossRefGoogle Scholar
  88. 88.
    Schulte-Wissermann H, Zepp F (1983) Indikationen und Nutzen der Immunglobulintherapie. Pädiat Prax 28:651–659.Google Scholar
  89. 89.
    Schultze HE, Schwick G (1962) Über neue Möglichkeiten intravenöser Gammaglobulin-Appli-kation. Dtsch Med Wochenschr 87:1643.PubMedCrossRefGoogle Scholar
  90. 90.
    Schumacher K (1986) Therapie mit Immunglobulinen. Dtsch Med Wochenschr 111:550–556.PubMedCrossRefGoogle Scholar
  91. 91.
    Sidiropoulos D, Straume B (1984) Treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobulin (IgG i.v.) Blut 48:383–386.PubMedCrossRefGoogle Scholar
  92. 92..
    Skvaril F (1986) Clinical relevance of IgG subclasses. In: Morell A, Nydegger UE (ed) Clinical use of intravenous immunoglobulins, Academic Press, Orlando, Florida pp. 37–45.Google Scholar
  93. 93.
    Skvaril F, Roth-Wicky B, Barandun S (1980) IgG subclasses in human γ-globulin preparations for intravenous use and their reactivity with staphylococcus protein A. Vox Sang 38:147–155.PubMedCrossRefGoogle Scholar
  94. 94.
    Stanley P, Cole P (1983) Intravenous immunoglobulin preparations. Lancet I:829.CrossRefGoogle Scholar
  95. 95.
    Stephan W (1975) Undegraded human immunoglobulin för intravenous use. Vox Sang 28:422–437.PubMedCrossRefGoogle Scholar
  96. 96..
    Steward MW (1984) Antibodies: Their structure and function, Chapman and Hall, London, New York.Google Scholar
  97. 97.
    Stiehm ER (1979) Standard and special human immune serum globulins as therapeutic agents. Pediatrics 63:301–319.PubMedGoogle Scholar
  98. 98.
    Stiehm ER (1986) Intravenous immunoglobulins in neonates and infants. Pediatr Infect Dis 5 (Suppl):217–219.Google Scholar
  99. 99.
    Stoll C, Schedel I, Peest D (1985) Serum antibodies against common antigens of bacterial li-popolysaccharides in healthy adults and in patients with multiple myeloma. Infection 13:23.CrossRefGoogle Scholar
  100. 100.
    Sugg U, Schneider W, Hoffmeister HE, Huth C, Stephan W, Lissner R, Haase W (1985) Hepatitis B immune globulin to prevent Non-A, Non-B post-transfusion hepatitis. Lancet 1:405–406.PubMedCrossRefGoogle Scholar
  101. 101.
    Sultan Y, Maisonneuve P, Kazatchkine MD, Nydegger UE (1984) Antiidiotypic suppression of autoantibodies to factor VIII (Antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 11:765–768.CrossRefGoogle Scholar
  102. 102.
    Sundqvist SB, Ljung R, Holmberg L (1983) Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Eur J Clin Invest 13:A42.Google Scholar
  103. 103.
    Tedder RS, Uttley A, Cheingsong-Popov R (1985) Safety of immunoglobulin preparation containing anti-HTLV-III. Lancet 1:815.PubMedCrossRefGoogle Scholar
  104. 104.
    Tilz GP (1986) Some side effects of intravenous 7S-immunoglobulins are due to immune complexes and can be prevented by 5S-immunoglobulin given prior to 7S treatment. Clin Exp Immunol 63:258–259.PubMedGoogle Scholar
  105. 105.
    Uchino H, Yasunaga K, Akatsuka JI (1984) A cooperative clinical trial of high-dose Immunglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura. Thromb Haemost 51:182–185.PubMedGoogle Scholar
  106. 106.
    Werner C (1985) Immunglobuline. Krankenhauspharmazie 6:521–523.Google Scholar
  107. 107.
    WHO/IUIS Report (1982) Appropriate uses of human immunoglobulin in clinical practice. Bull WHO 60:43–47.Google Scholar
  108. 108.
    Winston DJ, Winston G, Lin CH, Budinger MD, Champlin RD, Gale RP (1984) Intravenous immunoglobulin för modification of cytomegalovirus infections associated with bone marrow transplantation. Am J Med 76:128–133.PubMedCrossRefGoogle Scholar
  109. 109.
    Wong P, Itoh K, Yoshida S (1986) Treatment of thrombotic thrombocytopenic purpura with intravenous gamma globulin. N Engl J Med 314:385–386.PubMedGoogle Scholar
  110. 110.
    Zanetti AR, Dentico P, Vecchio Blanco C del, Sagnelli E, Villa E, Ferroni P, Bergamini F (1986) Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. J Med Virol 18:327–334.PubMedCrossRefGoogle Scholar
  111. 111.
    Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225–1230.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • C. Mueller-Eckhardt

There are no affiliations available

Personalised recommendations